1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- MORE
Global Gastrointestinal Diseases Therapeutics Market 2020-2024
The gastrointestinal diseases therapeutics market is poised to grow by $ 22.82 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. The reports on gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new product launches, and demand for biologics and targeted therapies. In addition, increasing incidence of gastrointestinal diseases is anticipated to boost the growth of the market as well.
The gastrointestinal diseases therapeutics market analysis includes drug class segment and geographic landscapes.
The gastrointestinal diseases therapeutics market is segmented as below:
By Drug Class
This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The gastrointestinal diseases therapeutics market covers the following areas:
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
The gastrointestinal diseases therapeutics market is poised to grow by $ 22.82 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. The reports on gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new product launches, and demand for biologics and targeted therapies. In addition, increasing incidence of gastrointestinal diseases is anticipated to boost the growth of the market as well.
The gastrointestinal diseases therapeutics market analysis includes drug class segment and geographic landscapes.
The gastrointestinal diseases therapeutics market is segmented as below:
By Drug Class
- Anti-inflammatory and immunosuppressors
- Acid neutralizers
- Other therapeutics
- North America
- Europe
- Asia
- ROW
This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The gastrointestinal diseases therapeutics market covers the following areas:
- Gastrointestinal diseases therapeutics market sizing
- Gastrointestinal diseases therapeutics market forecast
- Gastrointestinal diseases therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- MORE
Executive Summary
Geographic Landscape
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ billion)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Other1 - Market share 2019-2024 (%)
22: Comparison by Other1
23: Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024 ($ billion)
24: Anti-inflammatory and immunosuppressors - Year-over-year growth 2019-2024 (%)
25: Acid neutralizers - Market size and forecast 2019-2024 ($ billion)
26: Acid neutralizers - Year-over-year growth 2019-2024 (%)
27: Other therapeutics - Market size and forecast 2019-2024 ($ billion)
28: Other therapeutics - Year-over-year growth 2019-2024 (%)
29: Market opportunity by Other1
30: Customer landscape
31: Market share by geography 2019-2024 (%)
32: Geographic comparison
33: North America - Market size and forecast 2019-2024 ($ billion)
34: North America - Year-over-year growth 2019-2024 (%)
35: Europe - Market size and forecast 2019-2024 ($ billion)
36: Europe - Year-over-year growth 2019-2024 (%)
37: Asia - Market size and forecast 2019-2024 ($ billion)
38: Asia - Year-over-year growth 2019-2024 (%)
39: ROW - Market size and forecast 2019-2024 ($ billion)
40: ROW - Year-over-year growth 2019-2024 (%)
41: Key leading countries
42: Market opportunity by geography ($ billion)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: Abbott Laboratories - Overview
50: Abbott Laboratories - Business segments
51: Abbott Laboratories - Key offerings
52: Abbott Laboratories - Key customers
53: Abbott Laboratories - Segment focus
54: AbbVie Inc. - Overview
55: AbbVie Inc. - Business segments
56: AbbVie Inc. - Key offerings
57: AbbVie Inc. - Key customers
58: AbbVie Inc. - Segment focus
59: AstraZeneca Plc - Overview
60: AstraZeneca Plc - Business segments
61: AstraZeneca Plc - Key offerings
62: AstraZeneca Plc - Key customers
63: AstraZeneca Plc - Segment focus
64: Bausch Health Companies Inc. - Overview
65: Bausch Health Companies Inc. - Business segments
66: Bausch Health Companies Inc. - Key offerings
67: Bausch Health Companies Inc. - Key customers
68: Bausch Health Companies Inc. - Segment focus
69: Boehringer Ingelheim International GmbH - Overview
70: Boehringer Ingelheim International GmbH - Business segments
71: Boehringer Ingelheim International GmbH - Key offerings
72: Boehringer Ingelheim International GmbH - Key customers
73: Boehringer Ingelheim International GmbH - Segment focus
74: GlaxoSmithKline Plc - Overview
75: GlaxoSmithKline Plc - Business segments
76: GlaxoSmithKline Plc - Key offerings
77: GlaxoSmithKline Plc - Key customers
78: GlaxoSmithKline Plc - Segment focus
79: Johnson & Johnson - Overview
80: Johnson & Johnson - Business segments
81: Johnson & Johnson - Key offerings
82: Johnson & Johnson - Key customers
83: Johnson & Johnson - Segment focus
84: Merck & Co. Inc. - Overview
85: Merck & Co. Inc. - Business segments
86: Merck & Co. Inc. - Key offerings
87: Merck & Co. Inc. - Key customers
88: Merck & Co. Inc. - Segment focus
89: Takeda Pharmaceutical Co. Ltd. - Overview
90: Takeda Pharmaceutical Co. Ltd. - Product and service
91: Takeda Pharmaceutical Co. Ltd. - Key offerings
92: Takeda Pharmaceutical Co. Ltd. - Key customers
93: Takeda Pharmaceutical Co. Ltd. - Segment focus
94: UCB SA - Overview
95: UCB SA - Business segments
96: UCB SA - Key offerings
97: UCB SA - Key customers
98: UCB SA - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations
- Market Overview
- Market ecosystem
- Value chain analysis
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segments
- Comparison by Drug class
- Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024
- Acid neutralizers - Market size and forecast 2019-2024
- Other therapeutics - Market size and forecast 2019-2024
- Market opportunity by Drug class
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume driver – Demand led growth
- Market challenges
- Market trends
- Overview
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ billion)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Other1 - Market share 2019-2024 (%)
22: Comparison by Other1
23: Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024 ($ billion)
24: Anti-inflammatory and immunosuppressors - Year-over-year growth 2019-2024 (%)
25: Acid neutralizers - Market size and forecast 2019-2024 ($ billion)
26: Acid neutralizers - Year-over-year growth 2019-2024 (%)
27: Other therapeutics - Market size and forecast 2019-2024 ($ billion)
28: Other therapeutics - Year-over-year growth 2019-2024 (%)
29: Market opportunity by Other1
30: Customer landscape
31: Market share by geography 2019-2024 (%)
32: Geographic comparison
33: North America - Market size and forecast 2019-2024 ($ billion)
34: North America - Year-over-year growth 2019-2024 (%)
35: Europe - Market size and forecast 2019-2024 ($ billion)
36: Europe - Year-over-year growth 2019-2024 (%)
37: Asia - Market size and forecast 2019-2024 ($ billion)
38: Asia - Year-over-year growth 2019-2024 (%)
39: ROW - Market size and forecast 2019-2024 ($ billion)
40: ROW - Year-over-year growth 2019-2024 (%)
41: Key leading countries
42: Market opportunity by geography ($ billion)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: Abbott Laboratories - Overview
50: Abbott Laboratories - Business segments
51: Abbott Laboratories - Key offerings
52: Abbott Laboratories - Key customers
53: Abbott Laboratories - Segment focus
54: AbbVie Inc. - Overview
55: AbbVie Inc. - Business segments
56: AbbVie Inc. - Key offerings
57: AbbVie Inc. - Key customers
58: AbbVie Inc. - Segment focus
59: AstraZeneca Plc - Overview
60: AstraZeneca Plc - Business segments
61: AstraZeneca Plc - Key offerings
62: AstraZeneca Plc - Key customers
63: AstraZeneca Plc - Segment focus
64: Bausch Health Companies Inc. - Overview
65: Bausch Health Companies Inc. - Business segments
66: Bausch Health Companies Inc. - Key offerings
67: Bausch Health Companies Inc. - Key customers
68: Bausch Health Companies Inc. - Segment focus
69: Boehringer Ingelheim International GmbH - Overview
70: Boehringer Ingelheim International GmbH - Business segments
71: Boehringer Ingelheim International GmbH - Key offerings
72: Boehringer Ingelheim International GmbH - Key customers
73: Boehringer Ingelheim International GmbH - Segment focus
74: GlaxoSmithKline Plc - Overview
75: GlaxoSmithKline Plc - Business segments
76: GlaxoSmithKline Plc - Key offerings
77: GlaxoSmithKline Plc - Key customers
78: GlaxoSmithKline Plc - Segment focus
79: Johnson & Johnson - Overview
80: Johnson & Johnson - Business segments
81: Johnson & Johnson - Key offerings
82: Johnson & Johnson - Key customers
83: Johnson & Johnson - Segment focus
84: Merck & Co. Inc. - Overview
85: Merck & Co. Inc. - Business segments
86: Merck & Co. Inc. - Key offerings
87: Merck & Co. Inc. - Key customers
88: Merck & Co. Inc. - Segment focus
89: Takeda Pharmaceutical Co. Ltd. - Overview
90: Takeda Pharmaceutical Co. Ltd. - Product and service
91: Takeda Pharmaceutical Co. Ltd. - Key offerings
92: Takeda Pharmaceutical Co. Ltd. - Key customers
93: Takeda Pharmaceutical Co. Ltd. - Segment focus
94: UCB SA - Overview
95: UCB SA - Business segments
96: UCB SA - Key offerings
97: UCB SA - Key customers
98: UCB SA - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- MORE
The publisher recognizes the following companies as the key players in the global gastrointestinal diseases therapeutics market: Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA.
Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is strong product pipeline."
According to the report, one of the major drivers for this market is the increasing incidence of gastrointestinal diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is strong product pipeline."
According to the report, one of the major drivers for this market is the increasing incidence of gastrointestinal diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
Note: Product cover images may vary from those shown
